Navigation Links
News brief: Dermatologic infections in cancer patients treated with EGFRI therapy
Date:12/9/2009

Patients who experience dermatologic toxic effects from epidermal growth factor receptor inhibitors (EGFRIs) have a high prevalence of skin and nail infections, according to a new study published online December 9 in the Journal of the National Cancer Institute.

This new class of anticancer agents, the EGFRIs, is used against various cancers including lung, pancreatic, breast, head and neck, and colorectal cancers. Patients treated with EGFRIs frequently experience toxic effects such as eruptions of the face, dry, itchy skin and nail inflammation. These side effects affect quality of life, but the impact of these effects on the patients' physical health, such as their increased susceptibility to cutaneous infections, has not been ascertained.

To examine this issue, Mario E. Lacouture, M.D., at the department of dermatology at Northwestern University in Chicago, and colleagues collected data on 221 patients who were treated in a referral clinic for dermatologic toxic effects of EGFRIs. They examined associations between patient characteristics and the development of these infections.

The researchers found that 84 (38%) of the 221 patients showed evidence of skin and nail infections, and 29% developed bacterial infections at sites previously affected by dermatologic toxic effects. Fifty (22.6%) of the 221 patients had cultures positive for Staphylococcus aureus, and 12 (5.4%) of the 221 patients cultured positive for methicillin-resistant S. aureus, which could be resistant to many common antibiotics.

The authors write that "in addition to treating the characteristic dermatologic toxic effects, attention should be paid to preventing or treating complicating infections, with the goal of maintaining quality of life and dermatologic health, both of which are essential for the optimization of EGFRI therapies in cancer patients."


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. In brief: New prognostic indicator for patients with IPF
2. JNCI news brief: Improving the biomarker pipeline for early cancer detection
3. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
4. JNCI news brief: Breast cancer hormone receptor status and risk of a second primary tumor
5. JNCI news brief: Antibody linked to chemotherapy drug inhibits ovarian cancer in lab
6. JNCI news brief: High serum insulin levels and risk of prostate cancer
7. JNCI news brief: Surgeon training found effective in breast cancer sentinel lymph node trial
8. JNCI news brief: Melanosome dynamics and sensitivity of melanoma cells to chemotherapy
9. JNCI news brief: STD confirmed to be associated with increased risk of prostate cancer
10. News brief: Effects of aspirin and folic acid on inflammation markers for colorectal adenomas
11. News brief: Long-term testicular cancer survivors at high risk for neurological side effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: